Article Correctness Is Author's Responsibility: Glial Cell Therapy Gets FDA’s Orphan Drug Designation for Transverse Myelitis

The article below may contain offensive and/or incorrect content.

The Company has obtained Investigational New Drug clearance for Phase 1/2a trials of Q-Cells in both TM and amyotrophic lateral sclerosis.